+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction



Incorporating platelet glycoprotein IIb/IIIa inhibition in critical pathways: unstable angina/non-ST-segment elevation myocardial infarction



Clinical Cardiology 22(8 Suppl): Iv30



Platelet glycoprotein (GP) IIb/IIIa inhibitors have been shown to be effective in reducing thrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary intervention (PCI) and when used as medical therapy in patients with unstable angina/non-ST-segment elevation myocardial infarction (MI). Recent findings include dramatic preventive benefits in the setting of coronary stent deployment and a significant long-term preventive effect on mortality. The benefits of GP IIb/IIIa receptor inhibition suggest the utility of adopting routine use of these agents in critical pathways of unstable angina/non-ST-segment elevation MI and PCI. Because cost constraints may limit use of these agents, however, targeting treatment based on patient risk assessment may be warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046373412

Download citation: RISBibTeXText

PMID: 10492851

DOI: 10.1002/clc.4960221606


Related references

Update: Use of platelet glycoprotein IIb/IIIa inhibitors in patients with unstable angina and non-ST-segment elevation myocardial infarction. Annals of Emergency Medicine 56(5): E1, 2010

Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction. Cochrane Database of Systematic Reviews 2001(4): Cd002130, 2001

Evidence-based emergency medicine. Use of platelet glycoprotein IIb/IIIa inhibitors in patients with unstable angina and non-ST-segment elevation myocardial infarction. Annals of Emergency Medicine 40(5): 518-520, 2002

Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction. Coronary Artery Disease 10(8): 561-566, 1999

Glycoprotein IIb/IIIa inhibitors in patients with unstable angina/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines. American Heart Journal 146(4 Suppl): S18, 2003

Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department. Journal of Emergency Medicine 19(3 Suppl): 13s, 2000

Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?. Journal of Clinical Pharmacy and Therapeutics 29(6): 497-510, 2004

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England Journal of Medicine 338(21): 1488-1497, 1998

Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 102(20): 2466-2472, 2000

Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). American Heart Journal 146(4): 668-673, 2003

Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction A comparison of the thrombolysis in myocardial infarction IIIB trial and the treat angina with aggrastat and determine cost of therapy with invasive or conservative strategy -TIMI 18 trial. Circulation 109(7): 874-880, 2004

Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction. Emergency Medicine Australasia 17(5-6): 500-510, 2005

Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines. Journal of Invasive Cardiology 15(2): 102-7; Quiz 108, 2003

Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Journal of Invasive Cardiology 17(6): 300-301, 2005

Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial. Circulation 109(7): 874-880, 2004